Company news

Shanghai Fosun Pharmaceutical (Group) Co., Ltd. news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

Announcement on Acceptance of Drug Registration Application of Holding Subsidiary

May 13, 2026

Notice on Convening the 2025 Annual General Meeting, the 2nd A-Share Shareholders' Meeting in 2026, and the 2nd H-Share Shareholders' Meeting in 2026

May 11, 2026

Announcement on Holding Subsidiary’s Drug Obtaining Approval for Clinical Trial from FDA

May 10, 2026

Fosun Pharma Announces Q1 2026 Results: Net Profit Attributable to Shareholders After Deducting Non-Recurring Gains and Losses Increased by 21.96% YoY, With Strong Pipeline Execution

April 28, 2026

Arcera Life Sciences and Fosun Pharma launch long-term collaboration framework

April 28, 2026

Announcement on Progress in Participation in Establishing a Private Equity Investment Fund and Proposed Disposal of Assets

April 23, 2026

Fosun Health เสริมความแกร่งระดับภูมิภาคที่ GlobalHealth Asia-Pacific Forum 2026 อวด "China Solution" พร้อมกวาดสามรางวัลใหญ่

April 23, 2026

Announcement on the Pledge of Partial Shares Held by Shareholders

April 15, 2026

Announcement on Approval of Supplementary Drug Application by Holding Subsidiary

April 9, 2026

Announcement on Change of Chief Financial Officer

April 2, 2026

Announcement on Participating in Setting up Private Equity Investment Fund

March 31, 2026

Announcement on Proposed Expansion of Financial Leasing Business by a Holding Subsidiary

March 24, 2026

Announcement on Resolutions of the Convening of the 2026 1st Extraordinary General Meeting, the 2026 1st A-share General Meeting and the 2026 1st H-share General Meeting

February 27, 2026

Self-Inspection Report on Trading of the Company's Shares by Insiders Related to the Spin-off and Listing of a Subsidiary on the Main Board of the Stock Exchange of Hong Kong Limited

February 26, 2026

Indicative Announcement on Convening of the 2026 1st Extraordinary General Meeting, the 2026 1st A-share General Meeting and the 2026 1st H-share General Meeting

February 25, 2026

Announcement on Progress in Signing the Licensing Agreement of Wholly-owned Subsidiary

February 24, 2026

Announcement on Signing License Agreement by Holding Subsidiary

February 5, 2026

Notice of the Convening of the 2026 1st Extraordinary General Meeting, the 2026 1st A-share General Meeting and the 2026 1st H-share General Meeting

February 4, 2026

Announcement on Completion of Issuance of the 2026 Phase I Science and Technology Innovation Bonds

February 3, 2026

Announcement on Resolutions of the 23rd (Extraordinary) Meeting of the 10th Board of Directors

January 27, 2026

Announcement on Pledge and Release of Pledge of Partial Shares of Shareholder

January 23, 2026

Announcement on Resolutions of the 22nd (Extraordinary) Meeting of the 10th Board of Directors

January 22, 2026

Announcement on Completion of Filing with China Securities Regulatory Commission for Application for Full Circulation of Domestic Unlisted Shares of Holding Subsidiary

January 16, 2026

Announcement on Progress in Implementation of the Incentive Plan by a Holding Subsidiary

January 14, 2026

Announcement on Completing Private Investment Fund Filing for Subscribed Equity Investment Fund

January 5, 2026

Announcement on Progress in Participating in the Establishment of Private Equity Investment Fund

December 31, 2025

Announcement on Holding Subsidiary's Progress in Drug Clinical Trials

December 30, 2025

Announcement on Completion of 2022 Non-public Offering Funded Projects and Closure of Special Accounts

December 24, 2025

Announcement on Reply to Shanghai Stock Exchange's "Letter of Regulation in Outward Investment"

December 22, 2025

Announcement on Signing Cooperation and Option Agreement by Holding Subsidiary

December 18, 2025

Announcement on Outward Investment

December 15, 2025

Fosun Pharma's Subsidiary Yao Pharma and Pfizer Enter into Exclusive Collaboration and License Agreement

December 9, 2025

Fosun Pharma Announces 2025Q3 Financial Results

October 28, 2025

Fosun Pharma Announces 2025 Interim Results

August 26, 2025

Fosun Pharma's Self-Developed Innovative Drug Luvometinib Tablets Gains Breakthrough Therapy Designation in Saudi Arabia

August 19, 2025

Fosun Pharma's Small Molecule Innovative Drug XH-S004 Achieves Overseas Licensing for a Potential Total of $645 Million

August 11, 2025

Fosun Pharma’s Self-Developed New Drug XH-S004 for the Treatment of Chronic Obstructive Pulmonary Disease Enters Phase 1b Clinical Trial

July 17, 2025

Fosun Pharma's Self-developed Innovative Drug Luvometinib Tablets for the Treatment of Pediatric Low-grade Glioma Indication Enters Phase 3 Clinical Trial in China

July 9, 2025

Shanghai Fosun Pharmaceutical (Group): Fosun Pharma Completes Board Election, Accelerating Innovation Transformation and Global Development

June 24, 2025

Teva and Fosun Pharma Enter into a Strategic Partnership to Develop Novel Anti-PD1-IL2 Therapy (TEV-56278) in Immuno-Oncology

June 16, 2025

Fosun Pharma Announces 2024 Annual Results

March 24, 2025

Fosun Pharma Received NMPA Approval for Wan Ti Le (Tenapanor Hydrochloride Tablets)

February 26, 2025

Fosun Pharmaceutical Deeply Embraces AI, Self-developed PharmAID Decision Intelligence Platform Boosts Efficient Innovation

February 17, 2025

Fosun Pharma’s Self developed anti PD 1 mAb Serplulimab Approved in the EU for First Line Treatment of Extensive Stage Small Cell Lung Cancer (ES SCLC)

February 6, 2025

Fosun Pharma and Insightec Establish Joint Venture to Expand Global Access to Focused Ultrasound Treatment for Neurological Diseases

December 11, 2023

Shanghai Fosun Pharmaceutical (Group): COMIRNATY® Bivalent COVID-19 Vaccine is Officially Approved as Regular Imported Vaccine by the Pharmaceutical Administration Bureau of Macao SAR

January 20, 2023

Self-Paid Vaccination Service for Bivalent COVID-19 Vaccine COMIRNATY® is Officially Provided in Hong Kong, Offering More Vaccine Options for People in Need

January 5, 2023

Shanghai Fosun Pharmaceutical (Group): Fosun Pharma Announces Results for the First Three Quarters of 2022

October 29, 2022

Voluntary announcement - entering into sale and purchase agreements (h shares)

June 6, 2022

Monthly return of equity issuer on movements in securities for the month ended 31 May 2022(h shares)

June 1, 2022

← Newer news releases · Older news releases →

Decks